Li Zhou is a politics reporter at Vox, with a focus on national issues in the United States. She has previously worked as a tech policy reporter at Politico and as a fellow at The Atlantic. Li's articles cover a range of topics including congressional politics, abortion rights, global conflicts, and scientific research.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Li Zhou's coverage is primarily focused on Government & Politics, with a significant emphasis on Legal Policy Regulation and Government Announcements. She delves into evolving stories within the political landscape, often citing relevant data to support her articles.
Considering Li's national focus in the United States, she would likely be interested in receiving pitches from experts who can provide insights or analysis related to US government policies, legal regulations, and ongoing political developments. Given her interest in global issues and specific topics such as abortion and climate change, providing nuanced perspectives or new data related to these areas might also capture her attention.
Experts well-versed in US politics, policy formulation processes, legal nuances of regulatory changes could find success with their outreach efforts towards Li Zhou.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The move helps give overlooked Black players the credit they deserve.
It's the latest — and perhaps strangest — escalation in tensions between the two countries.
Deepfakes are being weaponized against women. The chart-topping rapper is the latest target.
Republicans' vote to hold him in contempt, briefly explained.
The troubling corporate pullback on Pride Month, briefly explained.
In recent months, he’s worked with the likes of everyone from Beyoncé to Taylor Swift to Morgan Wallen.
A foul from Carter sparked a debate that taps into racist and sexist tropes.
Rep. Jamaal Bowman, a member of the Squad, is being challenged because of his critiques of Israel.
Seasonal depression can hit in warmer months, too. Here’s how to cope.
By: Li Zhou, Joey W Y Chan, Yaping Liu, Jihui Zhang, Shirley X Li, Steven W H Chau, Vincent Mok, Shi Tang, Yun Kwok Wing, Jing Wang, Bei Huang
Objective While isolated rapid eye movement sleep behaviour disorder (iRBD) is known as a prodrome of α-synucleinopathies, the prediction for its future phenoconversion to parkinsonism-first or dementia-first subtype remains a challenge. This study aimed to investigate whether visuospatial dysfunction predicts dementia-first phenoconversion in iRBD.Methods Patients with iRBD and control subjects were enrolled in this prospective cohort study. Baseline neuropsychological assessment included the Unified Parkinson’s Disease Rating Scale part III, Montreal Cognitive Assessment (MoCA), Rey-Osterrieth complex figure (ROCF), Colour Trails test (CTT), Farnsworth-Munsell 100-hue test and Digit Span test. The anterior and posterior subscores of MoCA as well as their modified versions were explored. A composite score derived from ROCF and CTT was also explored. Regular follow-up was conducted to determine the phenoconversion status of iRBD patients.Results The study included 175 iRBD patients and 98 controls. During a mean follow-up of 5.1 years, 25.7% of patients experienced phenoconversion. Most of the neuropsychological tests could differentiate dementia-first but not parkinsonism-first convertors from non-convertors. The modified posterior subscore of MoCA, by integrating the Alternating Trail Making and Clock Drawing components into original the posterior subscore, which mainly reflects visuospatial function, was the strongest predictor for dementia-first phenoconversion (adjusted HR 5.48, 95% CI 1.67 to 17.98).Conclusion Visuospatial dysfunction, as reflected mainly by the modified posterior subscore of MoCA, is a predictive factor for dementia-first phenoconversion in iRBD, suggesting its potential for being a biomarker for clinical prognostic prediction and potential neuroprotective trials aiming to delay or prevent dementia.Data are available on reasonable request. The data collected in this study were not planned to be made to the public currently but might be available on reasonable request to the corresponding author.
(833) 317-6278 
